Neurobehavioral drug developer BlackThorn Therapeutics has named Gregory Vontz its CEO. Vontz comes to the South San Francisco-based company from Topica Pharmaceuticals, where he was president and CEO. His experience also includes positions at Connetics, Genentech, and Merck. Last October, BlackThorn raised $40 million in a Series A round that the company planned to apply toward development of four drug candidates in its pipeline.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
